A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Summary

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after treatment with the vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no signs of inflammation. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a clinical response will receive either a high dose or low dose of vedolizumab once every 8 weeks.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Crohn's Disease (CD)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

2 to 17 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Takeda

Last updated on ClinicalTrials.gov

May 5, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites